Skip to main
GOVX
GOVX logo

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc. is demonstrating a robust trajectory in its clinical programs, particularly with the GEO-CM04S1 COVID-19 vaccine, which has shown positive Phase 2 performance among immunocompromised populations and ongoing trials targeting hematologic cancers. The company is capitalizing on favorable regulatory feedback for its Mpox/Smallpox vaccine and has expanded collaboration efforts for innovative delivery methods, further enhancing its product pipeline. Additionally, management's proactive approach to improving liquidity and monitoring M&A dynamics signals a strategic focus that could bolster financial stability and investor confidence amidst the current distressed valuation level.

Bears say

The financial outlook for Geovax Labs Inc. is negatively impacted by limited liquidity, a depressed share price, and a challenging financing environment, which heightens the execution risk associated with the company's operations. As of the end of Q3, Geovax's cash position stood at only $5 million, with substantial ongoing cash burn related to research and development, indicating a pressing need for additional financing amid a sector where nearly 40% of public biotechs may exhaust their cash within the next year. Furthermore, the overall cautious approach from biotechnology investors diminishes capital availability, leading to a reassessment of Geovax's valuation and increasing concerns over potential dilution risks and funding uncertainties.

Geovax Labs (GOVX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Geovax Labs (GOVX) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.